Evidence map›Paper›PMID 34031362›Full record

ArticleTranslational psychiatry2021

Multimodal prognosis of negative symptom severity in individuals at increased risk of developing psychosis.

Daniel J Hauke, André Schmidt, Erich Studerus, Christina Andreou, Anita Riecher-Rössler, Joaquim Radua, Joseph Kambeitz, Anne Ruef, Dominic B Dwyer, Lana Kambeitz-Ilankovic and 20 more

Abstract read
In one paragraph

Article in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Daniel J Hauke *Department of Psychiatry (UPK), University of Basel, Basel, Switzerland. daniel.hauke@unibas.ch.ORCID 0000-0003-1772-9239
André Schmidt *Department of Psychiatry (UPK), University of Basel, Basel, Switzerland.ORCID 0000-0001-6055-8397
Erich StuderusDepartment of Psychology, University of Basel, Basel, Switzerland.
Christina AndreouDepartment of Psychiatry (UPK), University of Basel, Basel, Switzerland.
Anita Riecher-RösslerDepartment of Psychiatry (UPK), University of Basel, Basel, Switzerland.ORCID 0000-0001-6361-8789
Joaquim RaduaImaging of Mood- and Anxiety-Related Disorders (IMARD) Group, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), CIBERSAM, Barcelona, Spain.
Joseph KambeitzDepartment of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.ORCID 0000-0002-8988-3959
Anne RuefDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.
Dominic B DwyerDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.
Lana Kambeitz-IlankovicDepartment of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
Theresa LichtensteinDepartment of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
Rachele SanfeliciDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.
Nora PenzelDepartment of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
Shalaila S HaasDepartment of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID 0000-0003-1385-1050
Linda A AntonucciDepartment of Education, Psychology, Communication, University of Bari Aldo Moro, Bari, Italy.
Paris Alexandros LalousisInstitute for Mental Health and Centre for Human Brain Health, University of Birmingham, Birmingham, UK.ORCID 0000-0001-9642-3080
Katharine ChisholmInstitute for Mental Health, University of Birmingham, Birmingham, UK.
Frauke Schultze-LutterDepartment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.ORCID 0000-0003-1956-9574
Stephan RuhrmannDepartment of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.ORCID 0000-0002-6022-2364
Jarmo HietalaDepartment of Psychiatry, University of Turku, Turku, Finland.ORCID 0000-0002-3179-6780
Paolo BrambillaDepartment of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0000-0002-4021-8456
Nikolaos KoutsoulerisDepartment of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Munich, Germany.ORCID 0000-0001-6825-6262
Eva MeisenzahlDepartment of Psychiatry and Psychotherapy, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
Christos PantelisMelbourne Neuropsychiatry Centre, University of Melbourne & Melbourne Health, Carlton South, VIC, Australia.ORCID 0000-0002-9565-0238
Marlene RosenDepartment of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital, University of Cologne, Cologne, Germany.
Raimo K R SalokangasDepartment of Psychiatry, University of Turku, Turku, Finland.
Rachel UpthegroveInstitute for Mental Health and School of Psychology, University of Birmingham, Birmingham, UK.ORCID 0000-0001-8204-5103
Stephen J WoodInstitute for Mental Health, University of Birmingham, Birmingham, UK.
Stefan BorgwardtDepartment of Psychiatry (UPK), University of Basel, Basel, Switzerland.ORCID 0000-0002-5792-3987
PRONIA Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Negative symptoms occur frequently in individuals at clinical high risk (CHR) for psychosis and contribute to functional impairments. The aim of this study was to predict negative symptom severity in CHR after 9 months. Predictive models either included baseline negative symptoms measured with the Structured Interview for Psychosis-Risk Syndromes (SIPS-N), whole-brain gyrification, or both to forecast negative symptoms of at least moderate severity in 94 CHR. We also conducted sequential risk stratification to stratify CHR into different risk groups based on the SIPS-N and gyrification model. Additionally, we assessed the models' ability to predict functional outcomes in CHR and their transdiagnostic generalizability to predict negative symptoms in 96 patients with recent-onset psychosis (ROP) and 97 patients with recent-onset depression (ROD). Baseline SIPS-N and gyrification predicted moderate/severe negative symptoms with significant balanced accuracies of 68 and 62%, while the combined model achieved 73% accuracy. Sequential risk stratification stratified CHR into a high (83%), medium (40-64%), and low (19%) risk group regarding their risk of having moderate/severe negative symptoms at 9 months follow-up. The baseline SIPS-N model was also able to predict social (61%), but not role functioning (59%) at above-chance accuracies, whereas the gyrification model achieved significant accuracies in predicting both social (76%) and role (74%) functioning in CHR. Finally, only the baseline SIPS-N model showed transdiagnostic generalization to ROP (63%). This study delivers a multimodal prognostic model to identify those CHR with a clinically relevant negative symptom severity and functional impairments, potentially requiring further therapeutic consideration.

Indexed as

Prodromal SymptomsPsychotic DisordersBrainHumansPrognosisRisk Factors

Identifiers

PMID34031362
PMCPMC8144430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.